Terns Pharmaceuticals (NASDAQ:TERN) Lowered to “Sell” Rating by Wall Street Zen

Terns Pharmaceuticals (NASDAQ:TERN) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

TERN has been the topic of several other research reports. Jefferies Financial Group reiterated a “buy” rating and set a $70.00 price objective on shares of Terns Pharmaceuticals in a research note on Wednesday, December 10th. Citigroup reissued an “outperform” rating on shares of Terns Pharmaceuticals in a report on Wednesday, November 26th. TD Cowen raised Terns Pharmaceuticals to a “strong-buy” rating in a report on Friday, February 20th. UBS Group upgraded Terns Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 4th. Finally, HC Wainwright boosted their price objective on Terns Pharmaceuticals from $20.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $58.11.

Terns Pharmaceuticals Stock Performance

Shares of NASDAQ:TERN opened at $48.44 on Friday. The company’s fifty day moving average is $39.70 and its two-hundred day moving average is $27.52. Terns Pharmaceuticals has a 1-year low of $1.87 and a 1-year high of $50.00. The stock has a market capitalization of $5.03 billion, a price-to-earnings ratio of -47.03 and a beta of -0.31.

Insider Activity at Terns Pharmaceuticals

In related news, insider Emil Kuriakose sold 1,155 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $38.57, for a total value of $44,548.35. Following the completion of the transaction, the insider directly owned 50,365 shares of the company’s stock, valued at $1,942,578.05. This represents a 2.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Amy L. Burroughs sold 14,583 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $46.71, for a total value of $681,171.93. Following the completion of the sale, the chief executive officer owned 288,976 shares in the company, valued at approximately $13,498,068.96. This represents a 4.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 170,409 shares of company stock worth $6,563,769 in the last 90 days. 1.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Terns Pharmaceuticals during the fourth quarter valued at about $25,000. GAMMA Investing LLC lifted its stake in shares of Terns Pharmaceuticals by 762.4% in the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock worth $35,000 after acquiring an additional 770 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Terns Pharmaceuticals by 61.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,207 shares of the company’s stock valued at $89,000 after acquiring an additional 841 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Terns Pharmaceuticals by 5.1% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 18,555 shares of the company’s stock valued at $750,000 after acquiring an additional 906 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Terns Pharmaceuticals by 29.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,377 shares of the company’s stock valued at $177,000 after acquiring an additional 994 shares during the period. Institutional investors own 98.26% of the company’s stock.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.